<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9717249</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36321</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Protoc Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Protoc Pharmacol</journal-id>
<journal-title-group>
<journal-title>Current protocols in pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1934-8282</issn>
<issn pub-type="epub">1934-8290</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28892145</article-id>
<article-id pub-id-type="pmc">5721518</article-id>
<article-id pub-id-type="doi">10.1002/cpph.25</article-id>
<article-id pub-id-type="manuscript">NIHMS887087</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>All-optical electrophysiology for disease modeling and pharmacological characterization of neurons</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Werley</surname>
<given-names>Christopher A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brookings</surname>
<given-names>Ted</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Upadhyay</surname>
<given-names>Hansini</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Luis A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McManus</surname>
<given-names>Owen B.</given-names>
</name>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dempsey</surname>
<given-names>Graham T.</given-names>
</name>
</contrib>
<aff id="A1">Q-State Biosciences, Cambridge, Massachusetts</aff>
</contrib-group>
<author-notes>
<corresp id="FN1"><label>*</label><email>owen.mcmanus@qstatebio.com</email>, (617) 945-5433</corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflicts of Interest:</bold> Authors on this paper work for Q-State Biosciences, a startup biotechnology company using the Optopatch technology and stem-cell disease models in drug discovery.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<day>11</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>78</volume>
<fpage>11.20.1</fpage>
<lpage>11.20.24</lpage>
<!--elocation-id from pubmed: 10.1002/cpph.25-->
<abstract>
<p id="P1">A key challenge for establishing a phenotypic screen for neuronal excitability is to measure membrane potential changes with high throughput and accuracy. Most approaches to probe excitability rely on methods that are invasive and low throughput, or that lack cell-specific information. These limitations have motivated the development of novel strategies for characterizing the electrical properties of cultured neurons. We have developed optogenetic technologies (<italic>Optopatch</italic>) that enable stimulation and recording of membrane voltage signals from cultured neurons with single-cell sensitivity and millisecond temporal resolution. Neuronal activity can be elicited using blue light activation of the channelrhodopsin variant, ‘CheRiff’. Action potentials and synaptic signals are measured using ‘QuasAr’, a fast and sensitive voltage-indicating protein, whose near-infrared fluorescence scales proportionately with transmembrane potential. This integrated technology of optical stimulation and recording of electrical signals enables investigation of neuronal electrical function with unprecedented scale and precision.</p>
</abstract>
<kwd-group>
<kwd>Optical electrophysiology</kwd>
<kwd>Optopatch</kwd>
<kwd>CheRiff</kwd>
<kwd>QuasAr</kwd>
<kwd>disease modeling</kwd>
<kwd>voltage indicator</kwd>
<kwd>optogenetics</kwd>
<kwd>induced pluripotent stem cell</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>